The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Novo Nordisk, Valo Health Announce Expanded $4.6B AI Partnership
Jan 08, 2025•over 1 year ago
Contract Type
partnership
BagsværdManufacturing
Description
Novo Nordisk and Valo Health have expanded their collaboration into an up-to-$4.6 billion-plus artificial intelligence partnership aimed at discovering and developing up to 20 treatments for obesity, type 2 diabetes, and cardiovascular disease. The partnership will combine Novo Nordisk’s expertise in cardiometabolic diseases with Valo’s Opal Computational Platform™ to glean insights from human genetic and longitudinal patient data.
Company Information
Company
Novo Nordisk
Location
Bagsværd, Capital Region of Denmark, Denmark
About
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries.
BagsværdManufacturing